• BioImagene (Cupertino, California) reported the launch of Virtuoso – the company's new digital pathology solution. Virtuoso is a comprehensive suite of web-based software applications that work with BioImagene's iScan slide scanners to provide an end-to-end workflow solution. It is a Role-Based system and it enables the various stakeholders, or roles – Pathologist, Histo-technologist, Lab Administrator, Clinician, etc – to improve the efficiency and quality of the various steps in the Anatomical Pathology workflow. It allows the user to scan glass slides and then perform a wide range of functions - view, manage, manipulate, analyze, report and collaborate – in the digital form.

• GE Global Research (Niskayuna, New York) said they have developed sophisticated signal processing algorithms for a wireless sensor that can classify different types of motion and closely monitor a person's breathing and heart rate. The company says this type of sensor could have advantages in monitoring premature babies in a neonatal intensive care unit (NICU). Premature infants have very sensitive and fragile skin, which can make it difficult to directly attach sensors to them. GE's new sensor could wirelessly monitor an infant's movements, including breathing and heart rate. Similarly, this sensor could be installed in a home for elder care or other outpatient monitoring.

• Metabolon (Research Triangle Park, North Carolina) reported the release of the mFocus TST (Tissue-based Sarcosine Test), a research-use-only assay that measures the level of sarcosine in a biological sample. Based on biomarkers identified in a study conducted by Metabolon to better understand the metabolic changes associated with prostate cancer progression, the assay reports a biochemistry-based measurement of prostate cancer aggressiveness. mFocus TST is the first in a series of new research tool offerings developed using Metabolon's proprietary biochemical profiling technology which is able to identify and measure hundreds of biochemicals and metabolites in a biological sample.

• Nephros (River Edge, New Jersey) said it has received initial responses from the FDA's review of the company's 510(k) submissions for dialysis devices. Nephros submitted a 510k application to the FDA for approval to market its leading-edge hemodiafiltration products for end-stage renal disease in the U.S. Nephros's OLpur MD220 filter is designed expressly for HDF therapy that employs Nephros's proprietary Mid-Dilution Diafiltration technology. Nephros's OLpur H2H Hemodiafiltration module enables existing dialysis machines to be used for HDF therapy. The Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules." These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient.

With record numbers of American soldiers returning from Iraq and Afghanistan with brain injuries, a case study from Neuro Kinetics (Pittsburgh) suggests that tests using its I-Portal NOTC (Neuro-Otologic Test Center) system can generate results that may indicate mild traumatic brain injuries (mTBI) that are not detected by other evaluation technologies. The case study features unique pre- and post-accident neuro-otologic test data gathered from one individual, a NKI employee who had undergone various I-Portal NOTC evaluations as part of routine product testing and then again after he suffered a bicycle accident last year.

• Positron (Indianapolis) reported the results from an independent study on radiation exposure of technologists administering FDG. Positron's Tech-Assist is a heavy duty syringe shield (PIG) mounted on a portable cart system. This system is designed to reduce or limit exposure, heavy lifting injuries and repetitive motion injuries that occur during Nuclear Medicine injection applications. The Tech-Assist was designed with the ALARA principles of Time, Distance, and Shielding in mind. The Tech-Assist uses tungsten for all shielding. The cart enables the user to transport the PIG to and from the injection room with ease and adjusts to various height levels allowing for the injection of ambulatory or supine patients.

• Provista Life Sciences (Phoenix) reported a limited national rollout of the BT Test, a new predictive blood test to aid healthcare providers in the early detection of breast cancer. Through a partnership with MedicExams, a national network of healthcare testing facilities, women can now take the BT Test in 27 states nationwide. The BT Test, or Biomarker Translation Test, finds multiple cancer-related proteins in the blood and combines the results with the patient's medical profile to help physicians in their efforts to find breast cancer as early as possible. Clinical research conducted on the BT Test showed an accuracy rate above 80%. MedicExams is a network of experienced medical professionals who conduct physical examinations, testing and personal health interviews, primarily for the life and health insurance industry.

• pSivida (Watertown, Massachusetts) reported the completion of enrollment of the BrachySil (P32 BioSilicon) dose-ranging clinical trial. This dose ranging study follows a safety study of BrachySil in patients with inoperable pancreatic cancer. This first study had shown BrachySil in combination with standard chemotherapy (gemcitabine) was well tolerated with no clinically significant adverse events related to the device. The data also showed disease control in 82% of patients and an overall median survival of people in the study of 309 days. BrachySil also was found to be easily deliverable by endoscopic ultrasound.

No Comments